KLF4 expression and apoptosis-related markers in gastric cancer

Journal of B.U.ON.

Volumn 18, Issue 3, 2013, Pages 695-702

  Krstic, Miljan ^a   Stojnev, S ^a   Jovanovic, I ^a   Marjanovic, G ^a  

^a UNIVERSITY OF NI   (Serbia)

Author keywords

Apoptosis; Fas; Gastric cancer; KLF4; p53; Survivin

Indexed keywords

FAS ANTIGEN; FLICE INHIBITORY PROTEIN; KRUPPEL LIKE FACTOR 4; PROTEIN BCL 2; PROTEIN P53; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH SURGERY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; AGED; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885733533     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2010; 60:277-300.
2. Miyahara R, Niwa Y, Matsuura T et al. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007; 22:1435-1442.
3. Tzanakis NE, Peros G, Karakitsos P et al. Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chir Belg 2009; 109:609-611.
4. Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacetr pylori. Gut 2011; 60:624-630.
5. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157:1415-1430.
6. Flandez M, Gulimeau S, Blache P, Augentlich LH. KLF4 regulation in intestinal epithelial cell maturation. Exp Cell Res 2008; 314: 3712-3723.
7. Wei D, Gong W, Kanai M et al. Drastic down-regulation of Krüppel like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 2005; 65:2746-2754.
8. Zhang N, Zhang J, Shuai L et al. Krüppel-like factor 4 negatively regulates β-catenin expression and inhibits the proliferation, invasion and metastasis of gastric cancer. Int J Oncol 2012; 40:2038-2048.
9. Yoon HS, Chen X, Yang VW. Krüppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem 2003; 278:2101-2105.
10. Rowland BD, Bernard R, Peepers DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005; 7:1074-1082.
11. Ishida M, Gomyo Y, Tatebe S, Ohfujin S, Ito H. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: Analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling. Virchows Arch 1996; 428:229-235.
12. Gabbert HE, Müller W, Schneides A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76:720-726.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds): AJCC Cancer Staging Manual (7th Edn). Springer-Verlag, New York, 2009, pp 117-126.
14. Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis 2010; 28:600-603.
15. Nakayama T, Ling ZQ, Mukaisho K, Hattori T, Sugihara T. Lineage analysis of early and advanced tubular adenocarcinomas of the stomach: Continuous or discontinuous? BMC Cancer 2010; 10:311.
16. Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004; 7:61-77.
17. Bosman FT, Carneiro F, Hruban RH, Theise ND (Eds): WHO Classification of Tumours of the Digestive System. International Agency for Research on Cancer Press, Lyon, France, 2010, pp 45-80.
18. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
19. Katz JP, Perreault N, Goldststein BG et al. Loss of KLF4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach. Gastroenterology 2005; 128:935-945.
20. Vangapandu H, Ai W. Kruppel like factor 4 (KLF4): a transcription factor with diverse context-dependent functions. Gene Ther Mol Biol 2009; 13:94-104.
21. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene 2004; 23:395-402.
22. Ohnishi S, Ohnami S, Laub F et al. Downregulation and growth inhibitory effect of epithelial-type Kruppel like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun 2003; 308:251-256.
23. Wang N, Liu ZH, Ding F, Wang XQ, Zhou CN, Wu M. Down-regulation of gut-enriched Kruppel-like factor expression in esophageal cancer. World J Gastroenterol 2002;8:966-970.
24. Foster KW, Ren S, Louro ID et al. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ 1999;10:423-434.
25. Foster KW, Frost AR, McKie-Bell P et al. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 2000; 60:6488-6495.
26. Krstic M, Katie V. Histological, mucinohistochemical and immunohistochemical features of gastric signet ring cell carcinoma. Vojnosanit Pregl 2008; 65:835-838.
27. Sellak H, Wu S, Lincoln TM. KLF4 and SOX9 transcription factors antagonize β-catenin and inhibit TCF-activity in cancer cells. Biochim Biophys Acta 2012; 1823:1666-1675.
28. Dang DT, Chen X, Feng J, Torbenson M, Dang LH, Yang VW. Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenicity. Oncogene 2003; 22:3424-3430.
29. Wei D, Kanai M, Huang S, Xie K. Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis 2006; 27:23-31.
30. Stojnev S, Golubovic M, Babovic P. TP53 gene mutations - from guardian of the genome to oncogene. Acta Med Medianae 2010; 49: 59-63.
31. Cho J-H, Kim WH. Altered topographic expression of p21WAF1/CIP1/SDI1, bcl2 and p53 during gastric carcinogenesis. Pathol Res Pract 1998; 194:309-317.
32. Vallböhmer D, Drebber U, Schneider PM et al. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis. J Surg Oncol 2009; 99:409-413.
33. Wang M, Wu D, Tan M et al. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric carcinoma in South China. Biochem Genet 2009; 47:559-568.
34. Wang W, Zhao J, Wang H et al. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression. Exp Cell Res 2010; 316:2456-2464.
35. Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y. The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One 2011; 6(12):e29670.
36. Bartchewsky W Jr, Martini MR, Squassoni AC et al. Effects of helicobacter pylori infection on the expressions of Bax and Bcl-2 in patients with chronic gastritis and gastric cancer. Dig Dis Sci 2010; 55:111-116.
37. Tsamandas AC, Kardamakis D, Tsiamalos P et al. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res 2009; 29:703-709.
38. Gomes TS, Oshima CT, Segreto HR et al. The extrinsic apoptotic signaling pathway in gastric adenocarcinomas assessed by tissue microarray. Pathol Res Pract 2011; 207:613-617.
39. Ye YW, Fu H, Zhou Y et al. Study on the different expression of molecular markers between cardiac cancer and distal gastric cancer and their correlations with clinicopathological features. Dig Surg 2009; 26:384-391.
40. Zheng HX, Cai YD, Wang YD et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 2012; doi: 10.1038/onc.2012.126 (in press).
41. Chen L, Park SM, Tumanov AV et al. CD95 promotes tumour growth. Nature 2010; 465:492-496.
42. Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K et al. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer 2010; 10:275.